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Abstract
Collagens contain cryptic polypeptide modules that regulate major cell functions, such as cell proliferation or death.
Collagen XVIII (C18) exists as three amino terminal end variants with specific amino terminal polypeptide modules. We
investigated the function of the variant 3 of C18 (V3C18) containing a frizzled module (FZC18), which carries structural
identity with the extracellular cysteine-rich domain of the frizzled receptors. We show that V3C18 is a cell surface heparan
sulfate proteoglycan, its topology being mediated by the FZC18 module. V3C18 mRNA was expressed at low levels in 21
normal adult human tissues. Its expression was up-regulated in fibrogenesis and in small well-differentiated liver tumors,
but decreased in advanced human liver cancers. Low FZC18 immunostaining in liver cancer nodules correlated with markers
of high Wnt/b2catenin activity. V3C18 (Mr=170 kD) was proteolytically processed into a cell surface FZC18-containing
50 kD glycoprotein precursor that bound Wnt3a in vitro through FZC18 and suppressed Wnt3a-induced stabilization of
b2catenin. Ectopic expression of either FZC18 (35 kD) or its 50 kD precursor inhibited Wnt/b2catenin signaling in
colorectal and liver cancer cell lines, thus downregulating major cell cycle checkpoint gatekeepers cyclin D1 and c-myc and
reducing tumor cell growth. By contrast, full-length V3C18 was unable to inhibit Wnt signaling. In summary, we identified a
cell-surface signaling pathway whereby FZC18 inhibits Wnt/b2catenin signaling. The signal, encrypted within cell-surface
C18, is released by enzymatic processing as an active frizzled cysteine-rich domain (CRD) that reduces cancer cell growth.
Thus, extracellular matrix controls Wnt signaling through a collagen-embedded CRD behaving as a cell-surface sensor of
proteolysis, conveying feedback cues to control cancer cell fate.
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Introduction
The cell surface matrix is a signaling platform integrating
bidirectional cues between cells and extracellular matrix (ECM),
which contains growth factors, proteases and bioactive polypep-
tides, thus controlling major signaling pathways. Cryptic bioactive
polypeptides become functional by structural or conformational
changes of parent ECM molecules, including proteolysis [1].
Collagen XVIII (C18) [2,3], the parent molecule of endostatin
[4], is expressed as three distinct variants by two separate promoters
and alternative splicing of one of the transcripts [3,5]. Promoter #1
generates variant #1 (V1C18), which is a ubiquitous structural
basement membrane component. Alternative splicing of transcripts
from promoter #2 generates variants #2 (V2C18) and #3 (V3C18)
[6,7], which are secreted under the control of both liver-specific and
ubiquitous transcription factors. V2C18 contains a 192-aa Domain
of Unknown Function-959 (DUF-959) at its N-terminus, followed
by sequences common to all variants [8]. V2C18 is secreted as a
plasma protein by hepatocytes [9] and its expression decreases in
advanced liver cancers [10]. V3C18 carries a 235-aa stretch with 10
conserved cysteines, bearing sequence and structural identities with
the extracellular cysteine-rich domain (CRD) of the frizzled (FZ)
receptors and the secreted frizzled-related proteins (SFRPs) [11].
Hence, we named this module FZC18.
In the Wnt/b2catenin signaling pathway, interaction of 10
different FZ cell-surface receptors with at least 19 Wnts can be
inhibited by a family of 5 SFRPs that bind to Wnts at the cell
surface. In the absence of Wnt, b2catenin is recruited into a
destruction complex, phosphorylated at conserved N-terminal
residues by GSK3b, and thus tagged for proteasomal degradation
[12]. In the nucleus, target genes of the pathway are repressed by
co-repressor binding to T-cell factor (TCF) transcription factors.
Wnt binding to FZ receptors blocks b-catenin phosphorylation,
which becomes resistant to proteasomal degradation. Consequent-
ly, b-catenin accumulates both in the cytoplasm and the nucleus,
displacing co-repressors from TCF and activating transcription of
target genes that regulate the balance between proliferation and
apoptosis, differentiation and metabolism, including cyclin D1, c-
myc [12] and glutamine synthetase (GS) [13].
Wnt/b2catenin signaling can be activated in human cancers by
oncogenic mutations or by epigenetic silencing of pathway
components. Respectively, 85% and 10% of sporadic colorectal
cancers (CRCs) have APC and b2catenin mutations [12].
Epigenetic inactivation of SFRP genes occurs early in CRC [14]
and restoring SFRP expression attenuates Wnt/b2catenin
signaling [15]. In 30–40% of human hepatocellular carcinomas
(HCCs), activation of the pathway results from b2catenin and
axin mutations [16] or epigenetic silencing of SFRP1 [17].
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1878We investigated whether FZC18 could regulate Wnt/b2cate-
nin signaling. We show that V3C18 mRNA expression decreases
in advanced HCCs. In addition, the N-terminus of the V3C18 is
partially processed to a FZC18 precursor (V3Nter) which pulls
down Wnt3a in vitro, suppresses Wnt/b2catenin signaling and
downstream gene expression, reduces tumor cell growth and
increases cell death in CRC and HCC cell lines carrying activating
b2catenin mutations. The biological activity of FZC18 is cryptic
within full-length C18, as it is activated by proteolytic release.
Results
Decreased expression of V3C18 in cancer cell lines and in
advanced primary liver cancers
We analyzed the mRNA levels of V3C18 in human tissues by
QRT-PCR (quantitative RT-PCR) using brain as a calibrator
(Figure 1B). V3C18 showed the highest levels in kidney, followed
by liver, placenta, lung, bone marrow and testis. The expression of
V3C18 was 2 to 14 folds lower in cell lines from human HCC,
CRC, breast cancer or embryonic kidney than in normal liver
(Figure 1C). In addition, in the well-differentiated mouse
hepatoma cell line mhAT3FS315, carrying a dominant negative
form of the HNF3 transcription factor, inhibiting expression of
genes controlling the hepatocyte phenotype [18], the expression of
V3C18 mRNA was 22% of that in the parental cell line mhAT3F
(Figure 1C).
Low expression of V2C18 is associated with tumor progression
and reduced disease-free survival in HCCs [10]. Although V2C18
and V3C18 share a common promoter, V3C18 is additionally
regulated by alternative splicing of FZC18 to produce V2 [7].
Analysis of mRNA arrays from 122 frozen liver samples included
normal livers from 19 subjects, 54 HCCs and 49 matching non
tumor livers. V3C18 mRNA levels were higher in fibrotic and
cirrhotic livers than in normal livers (Figure 1D), indicating that
the expression of V3C18 increases during tissue remodeling. Small
(#2 cm) well-differentiated HCCs showed higher V3C18 mRNA
levels than advanced HCCs. The mean6SD size of both groups
was 1.360.38 cm and 6.564.6 cm, respectively (p=3
207). As
previously shown for V2C18 [10], these findings indicate that
higher V3C18 mRNA expression may be associated with less
aggressive tumors.
V3C18 and its amino-terminal proteolyzed form V3Nter
localize at the cell surface through the FZC18 module
Human embryonic kidney cells secrete a ,45 kD amino-
terminal fragment of V3C18 containing the FZC18 module [7].
These data led us to construct an expression vector including the
natural signal peptide+DUF-959+FZC18 modules and 47 aa from
the Tsp-1C18 domain common to all C18 variants that we called
V3Nter (Figure 2A). As a control, V2Nter included the same
sequences, but lacked FZC18 (Figure 2A).
Transient transfection of V3Nter or V2Nter cDNAs in
mhAT3FS315 mouse hepatoma cells followed by immunocyto-
chemistry (Figure 2, B–F) showed that V3Nter highlighted cell-cell
boundaries (Figure 2, B, D and Movie S1) and cell membranes,
particularly at sites of cell-cell contact (Figure 2D), as well as the
cell surface (Figure 2E). By contrast, V2Nter was detected within
the cells (Figure 2C). The surface of some of the cells was covered
with V2Nter signal, with dispersing speckles detected on
neighboring cells (Figure 2F), suggesting secretion.
Transient transfection of full-length V3C18 (V3FL) or full-
length V2C18 (V2FL) cDNAs in mouse hepatoma cells followed
by confocal immunofluorescence confirmed the above findings.
V3FL outlined cell membranes (Figure S1B), whereas V2FL was
Figure 1. Reduced expression of FZC18 in advanced liver
cancers and cell lines. (A) Schematic of V3C18 showing DUF-959,
FZC18, Tsp-1 (thrombospondin-1) and ES (endostatin) modules. The
thick horizontal yellow line below FZC18 indicates the probe used. (B–
D) Relative mRNA expression of V3C18 by QRT-PCR in human tissues
(Human Total RNA Master Panel, Clontech, USA) (B) and in cell lines (C).
Assays were performed in triplicate with a coefficient of variation ,10%
and normalized to 18S. Brain (B) and liver (C) were used as calibrators.
(D) Relative V3 mRNA expression in human liver samples. Small
(#2 cm), well-differentiated HCCs are compared to advanced HCCs.
mRNA samples were blotted in triplicates onto nylon membranes and
arrays hybridized with
32P-labeled cDNA under linear-range conditions.
Densitometry readings were normalized with an 18S probe. Bar graphs
show mean6SD. The Mann Whitney’s ‘‘U’’ test was used. NS, non
significant; NT, non tumor livers.
doi:10.1371/journal.pone.0001878.g001
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boundaries showed no signal (Figure S1C). V2FL was also
observed within large intracellular vacuoles resembling Golgi
structures (Figure S1D). The cell surface showed fraying vesicles
positive for V2FL, suggesting secretion (Figure S1D). Strong
intracellular burden of V2Nter and V2FL in cells transiently
expressing these proteins at high levels is consistent with our
previous observation of intracellular signal for endogenous V2C18
in hepatocytes in vivo and is frequently observed in the case of other
abundantly secreted plasma or ECM proteins such as albumin or
fibronectin [9,10,19]. In addition, abundant intracellular material
in some of the cells expressing V2C18 or V3C18 in vitro and in vivo
suggested posttranslational maturation of these proteins (i.e.,
glycosylation, see below).
V3Nter is a cryptic inhibitor of Wnt/b2catenin signaling
SFRP1, SFRP2 and SFRP5 suppress b2catenin2T2cell factor
(TCF)-regulated transcription (CRT) from a TCF/LEF responsive
reporter in the CRC cell line HCT116 [15]. We asked whether
V3Nter and V3FL could inhibit Wnt/b2catenin signaling in cell
lines carrying activating b2catenin mutations, HCT116 (b2ca-
tenin DS45) and HepG2 (HCC, b2catenin D252140) and used
SFRP1 and SFRP5 as controls. Ectopic expression of SFRP1,
SFRP5 or V3Nter suppressed CRT in a dose-dependent manner
Figure 2. V3Nter localizes at the cell surface and inhibits Wnt/b2catenin signaling and downstream protein expression. (A) V3Nter
and V2Nter expression vectors. Thick horizontal color lines indicate the antibodies used. Blue box, 47-aa stretch from the Tsp-1C18 module. (B1-C3)
Confocal fluorescence microscopy of mhAT3FS315 mouse HCC cells transiently transfected with V3Nter (B1-B3) or V2Nter (C1-C3) cDNAs and probed
with anti-DUF-959, followed by anti-rabbit TRITC-labeled IgG (red). Three out of 15 representative images acquired at 500-nm intervals on the vertical
axis are shown. V3Nter (B1-B3) highlights intercellular spaces. V2Nter (C1-C3) is detected in the cytoplasm. Movie S1 shows a tridimensional
reconstruction of V3Nter cell surface staining using the 15 acquired images (original magnification x1000). Figure S1, B-D shows confocal microscopy
of V3FL and V2FL. (D-F) Fluorescence microscopy of mouse HCC cells transfected with either V3Nter (D and E) or V2Nter (F) cDNAs and incubated
with either anti-DUF-959, followed by anti-rabbit TRITC-labeled IgG (red) (D and F) or anti-V5 epitope tag, followed by anti-mouse FITC-labeled IgG (E).
(D) V3Nter outlines cell membranes and cell-cell boundaries (arrow). (E) V3Nter highlights the cell surface (arrows). (F) Secretion of V2Nter covers the
cell surface and is detected on neighboring cells as dispersing red speckles (arrows). (G) Dose-dependent changes in CRT in response to increasing
amounts of transiently transfected cDNA vectors. Reporter gene assays using a b2catenin-TCF reporter driven by wild-type (SUPER8XTOPFLASH,
white bars) or a negative control with mutated TCF binding sites (SUPER8XFOPFLASH, black bars). Results are means of three replicates from a
representative experiment. Three independent experiments were performed. Error bars represent standard deviations. Figure S1, E and F shows
changes in CRT in response to V3FL and V2FL. (H) Immunoblot of HCT116 cells transiently transfected and probed with the indicated cDNA vectors
(top) and antibodies (right). Hsc70 is a loading standard.
doi:10.1371/journal.pone.0001878.g002
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(Figure S1E), increased CRT in HCT116, but not in HepG2 cells.
The increase in CRT by V2Nter, V2FL and V3FL was also
observed in other cell lines. In the well-characterized human HCC
cell line Huh-7 (wild-type b-catenin, baseline Wnt/b2catenin
signaling [20]) Wnt1, V2FL and V3FL increased CRT by more
than 10 folds and V2Nter by 2.9 folds (Figure S1F). Similar results
were obtained in the mhAT3FS315 mouse HCC cell line (not
shown).
C18 is a heparan sulfate proteoglycan (HSPG), which contains
heparan sulfate attachment sites common to all variants [8]. Thus,
endogenous V2C18 and V3C18, as well as their full-length and
their amino-terminal constructs could be HSPGs. Consistently,
immunoblotting of proteoglycan-enriched fractions from a human
HCC with anti-FZC18, anti-DUF-959 and anti-Tsp-1C18
antibodies showed a high molecular weight smear typical of
HSPGs. Important mobility shift and epitope unmasking were
seen after digestion with heparin lyases, but not with chondroi-
tinase ABC (Figure S1, A and G). Transfection of V2FL and V3FL
in mouse hepatoma cells and detection of the most N-terminal
(DUF-959) and C-terminal (endostatin) epitopes, as well as
FZC18, confirmed the high molecular weight smear typical of
HSPG for V2FL and V3FL (Figure S1H). Indeed, V2FL was
detected in cell-conditioned medium (Figure S1H). By contrast,
V3FL was detected at high levels in cell layers but not in the
conditioned medium (Figure S1H), confirming its predominantly
cell-surface location (Figure S1B). Therefore, V2FL-HSPG and
V3FL-HSPG might locally increase Wnt concentration, thereby
increasing CRT activity, as has been shown for other HSPGs [21].
In addition, V2Nter and V3Nter share a C-terminal 47 amino-
acid stretch (Figure 2A) from the heparan sulfate attachment site of
C18 [8], probably explaining the slight increase in CRT by
V2Nter (Figure 2G and S1F).
Transient overexpression of V3Nter resulted in a reduced
protein content of total b-catenin, non phosphorylated b-catenin,
c-myc and cyclin D1 in HCT116 cells (Figure 2H). Consistently
with data on CRT, V2FL and V3FL did not reduce the protein
content of total and non phosphorylated b2catenin, cyclin D1 or
c-myc (Figure 2H). In addition, consistently with decreased cyclin
D1 protein expression, reporter gene assays using the cyclin D1
promoter [22] upstream of luciferase cDNA confirmed that
SFRP1, SFRP5 and V3Nter decreased cyclin D1 promoter
activity in HCT116 and HepG2 cells (Figure S1I). Remarkably,
overexpression of b-catenin increased cyclin D1 promoter activity
by 2.4 and 4.8 folds in HCT116 and HepG2 cell lines,
respectively. Taken together, these data show that V3Nter can
inhibit b-catenin signaling in cancer cells carrying activating b-
catenin mutations and that the biological activity of the frizzled
CRD is cryptic within full-length cell surface C18-HSPG.
V3Nter inhibits tumor cell growth through increased cell
death
Based on these findings, we analyzed the effects of V3Nter on
growth and death of tumor cells. Decreased colony formation
occurred in HCT116 and HepG2 cells overexpressing V3Nter.
Inhibition of clonogenesis by V3Nter, SFRP1 and SFRP5 were
within the same range in both cell lines (Figure 3, A and B). b-
catenin induced a ,30 % increase in colony formation in HCT116
and HepG2 cells, in consistency with data on cyclin D1 promoter
activity, thus supporting the hypothesis that despite activating b-
catenin mutations, cells can still respond to stimuli inducing further
increases in b-catenin levels. HCT116 cells overexpressing SFRP1,
SFRP5 or V3Nter showed chromatin condensation, nuclear
fragmentation, numerous apoptotic bodies and an overall low cell
density. By contrast, higher cell densities and rare apoptotic bodies
were seen in cells expressing V2Nter, b-catenin or vector alone
(Figure 3C). Numbers of morphologically apoptotic Hoescht-
stained cells and flow cytometry analysis of subG1 cells showed
that V3Nter induced tumor cell death within the same range as
SFRPs (25 to 35%) in HCT116 cells (Figure 3D). Similarly, SubG1
analysis on HepG2 cells showed 35–40% cell death (Figure 3E). As
expected, vector alone and V2Nter showed baseline levels of cell
death in HCT116 and HepG2 cells (Figure 3, D and E).
Amino terminal processing of V3Nter releases soluble
FZC18
HCT116 cell layers expressing V3Nter (Mr=53 kD, Figure 4A)
showed 80 kD and ,30–40 kD polypeptides (Figure 4B). We thus
studied the relevance of glycosylation and further proteolysis of
bioactive V3Nter in the mouse HCC cell line mhAT3FS315. This
cell line expresses endogenous V3C18 at very low levels
(Figure 1C), which is not detected by anti-human FZC18 antibody
(not shown). Figure 4C shows that V2Nter (Mr=30 kD) and
V3Nter migrated as high molecular weight smears typical of
proteoglycans, consistently with data shown in Figure S1, G and
H. This is explained by heparan sulfate attachment sites residing
within the 47-aa stretch common to all variants [8] present in
V2Nter and V3Nter constructs. Therefore, as has been shown for
other HSPGs [21], V2Nter may locally increase Wnt concentra-
tion, resulting in a slight increase in CRT. However, the strong
inhibition of Wnt/b2catenin signaling by V3Nter could offset the
slight increase in CRT by this 47 amino-acid stretch.
Analysis of mhAT3FS315 cell layers confirmed the 80 kD and
,30–40 kD FZC18-containing polypeptides detected in HCT116
cells (Figure 4D). Consistently with its predominant cell surface
topology, the ,80-kD V3Nter polypeptide was detected at much
lower levels in cell conditioned media than in cell layers, even after
loading a 10-fold higher amount of protein from conditioned
media than from cell layers (Figure 4D). Similarly, V3FL was not
detected in the conditioned medium (Figure S1H), suggesting that
it is fully deposited within the cell surface matrix. Indeed, V3Nter
is a noncollagenous domain, whereas V3FL contains both
noncollagenous and collagenous domains. Thus, V3FL may be
secreted as a triple helical homotrimer, being deposited in the
pericellular matrix through supramolecular assemblies with other
extracellular matrix molecules, such as laminins or cell surface
heparan sulfates, which bind C18 through the endostatin domain
[23]. In addition, V3FL may bind cell surface integrin receptors
through RGD sequences in the collagenous domains [2]. By
contrast, conditioned media showed a higher ratio of the 36 kD/
80 kD FZC18-containing polypeptides than cell layers (Figure 4D,
compare V3Nter in medium and in cell layers), suggesting that
proteolytic processing releases a soluble FZC18 polypeptide.
Digestion of V3Nter with N-glycosidase and Sialidase A
(Figure 4E) revealed ,50 and 48 kD polypeptides containing
FZC18, V5 and DUF-959 epitopes. In addition, a 36 kD
polypeptide contained FZC18 and V5, but not DUF-959,
suggesting that N-terminal processing of V3Nter results in the
release of FZC18. To test whether FZC18 alone was active, we
cloned the FZC18 module in frame with the IgK signal sequence
and a C-terminal c-myc tag (Figure S2A). Expression in
mhAT3FS315 cells revealed a soluble ,35 kD N-glycosylated
polypeptide in cell conditioned medium (Figure S2B). The close
correspondence between the calculated (Mr=31 kD) and the
experimentally detected (,35 kD) molecular mass of FZC18
suggested that sialylation may not reside within FZC18.
Consistently, Sialidase A digestion of V2Nter showed a ,20 kD
mobility shift (Figure S2C). Thus, sialic acid moieties in V3Nter
FZC18 & Wnt Signaling
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the above findings, sialic acid is known to target glycoproteins to
the extracellular side of the plasma membrane [24] and plays an
important role in cell surface recognition and signaling.
FZC18 suppresses Wnt/b2catenin signaling
FZC18 suppressed CRT and total and non-phosphorylated
b2catenin stabilization in a dose-dependent manner (Figure 5, A
and B). In addition, FZC18 downregulated cyclin D1 promoter
activity (Figure 5C) and decreased colony formation (Figure 5D)
by 75% compared with cells expressing vector alone. In contrast,
V2Nter induced a 21% increase in colony formation with respect
to empty vector (Figure 5D), consistently with data on CRT
(Figures 2G and S1F) and cyclin D1 promoter activity (Figure S1I).
Ectopic FZC18 binds Wnt3a and suppresses Wnt3a-
dependent activation of b2catenin signaling in vitro
EBNA-293 cells were cotransfected with His-tagged Wnt3a and
either mouse V3Nter or V2Nter expression vectors. Wnt3a pulled
down V3Nter but not V2Nter (Figure 6, A and B), as shown by
immunoblotting with anti-DUF-959 antibody. In addition,
previous incubation of transfected cells with increasing concen-
trations of a 15-aa peptide derived from the CRD of FZC18
competed with FZC18 pull-down by Wnt3a (Figure S3A),
suggesting that Wnt3a interacts directly with the CRD of
FZC18. Then, we searched for in silico models predicting the 3D
structure of the FZC18 CRD using threading algorithms that seek
for template proteins with well-characterized crystal structures in
PDB databases (Phyre www server). Two highly significant matches
were mouse SFRP3 and FZ8, showing 32% and 22% identity,
respectively. E-values were 1.4
215 for SFRP3 and 6.6
215 for FZ8,
with an estimated precision of 100% for both models. Similar
results were obtained by homology modeling using the www server
HHpred, indicating 100% probability that the predicted 3D
model of FZC18 CRD matches the templates SFRP3 and FZ8
(p=0). Next, we looked at the localization of the competing
peptide RH3 on the putative surface of the FZC18 CRD. Running
the above models on Protein Explorer 2.79 showed that RH3 lies
Figure 3. V3Nter decreases colony formation and induces tumor cell death in HCT116 and HepG2 cells. HCT116 (A, C and D) and HepG2
(B, E) cells were transfected with cDNA vectors and selected for 14 d (A and B), 4 d (C and E) or 6–8 d (D) with G418. (A and B) After hematoxylin
staining, colonies (seen as dark spots) were digitized using a video camera and counted with Scion Image (NIH). Histograms show colony formation
efficiencies relative to cells transfected with empty vector. (C) Hoescht 33342-stained cells photographed at 6200 magnification. Arrows indicate
apoptotic cells. (D) Hoescht cell counts show mean6SD percent apoptotic cells out of triplicate 300-cell counts from 6-well plates (blindly at 6200
magnification) at each time point. SubG1 shows mean6SD percent apoptotic cells out of triplicate 1610
4 cells from 6-well plates assessed by flow
cytometry at each time point. (E) Representative FL2-H histograms of HepG2 cells show percent SubG1 population.
doi:10.1371/journal.pone.0001878.g003
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addition, the competing peptide lies adjacent to and partially
overlaps residues involved in Wnt-mFZ8 CRD interactions [25].
Consistently, cotransfection of mouse Wnt3a and human FZC18
or V3Nter with a TCF-responsive reporter in the HEK293T and
in the Huh-7 cell lines showed that FZC18 and V3Nter suppressed
Wnt3a-induced CRT by more than 80% (Figure 6C). Taken
together, these data show that FZC18 may interact with Wnt3a,
suggesting that FZC18 may function as a SFRP-like bioactive
polypeptide quenching at least Wnt3a in the tumor microenvi-
ronment.
Negative correlation between FZC18 expression and
b2catenin pathway activity in vivo
Immunoreactivity for FZC18, b2catenin and for the positive
target of Wnt signaling glutamine synthetase (GS) was assessed on
serial sections of normal, cirrhotic livers and HCCs (Figure 7). The
intensity was semi-quantitatively recorded using a 5-point scale,
from absent (2) to strong (++++), by comparing the staining in the
tumor with adjacent non-tumor tissue, as described [26]. In
normal liver, FZC18 was periportal (Figure 7A), contrasting with
the well-characterized pericentral vein localization of GS
(Figure 7B) [13], indicating that FZC18 epitopes are detected in
zones of low b2catenin pathway activation.
In HCCs, mild FZC18 signal was detected at sites where GS
was strong and b2catenin was cytoplasmic or nuclear (Figure 7,
D–F). Conversely, strong FZC18 signal was detected at sites where
GS staining was mild and b2catenin was associated with cell
membranes (Figure 7, G–L). Consistently, statistical analysis of
data from 24 tumor nodules indicated that FZC18 was negatively
correlated with GS (c=20.42; p=0.02; n=24) and cytoplasmic
b2catenin staining (c=20.47; p=0.02; n=23). Conversely,
FZC18 was positively correlated with cell membrane b2catenin
staining (c=0.67; p,0.001; n=23). As expected [26], nuclear and
cytoplasmic b2catenin were positively correlated (c=0.89;
p,0.001; n=23), as well as GS and nuclear (c=0.74; p,0.001;
n=23) or cytoplasmic b2catenin (c=0.63; p,0.001; n=23).
These data suggest that the FZC18 module could inhibit Wnt/
b2catenin signaling in the tumor microenvironment.
Proteolytic processing of V3C18 in cancer tissues in vivo
Immunoblot analysis using anti-FZC18 antibody on whole
protein extracts from histologically representative cryosections
from normal and tumor livers (Figure 8, B and C) showed a
,170 kD polypeptide consistent with V3FL (Mr=178 kD) in 4/4
normal and 4/6 tumor livers (Figure 8B). In addition, a prominent
polypeptide band was detected below the 74 kD marker in all
tumors but not in normal livers (Figure 8B). Search for further
Figure 4. Processing of V3Nter releases FZC18. (A) Schematic of V3Nter (left) and V2Nter (right) cDNA vectors. Horizontal color lines below each
module indicate the antibodies used. (B) Immunoblot of protein extracts from HCT116 cells transfected with the indicated cDNAs, resolved in
denaturing 7.5% PAGE-SDS and probed with anti-V5 (red). V3Nter shows ,80 kD and ,30–40 kD polypeptides. (C–E) Protein extracts from
mhAT3FS315 cells transfected with the indicated cDNAs. Denaturing 5% (C) or 7.5% (D–E) PAGE-SDS gels. (C) V2Nter and V3Nter appear as smears
typical of proteoglycans. (D) Asterisk, immunoglobulins from medium containing FCS. V2Nter shows a ,50 kD polypeptide in cell layers (L) and
conditioned medium (M). V3Nter shows ,80 kD and ,30–40 kD polypeptides in cell layers (L). By contrast, in medium (M), a 36 kD polypeptide
predominates and the 80 kD form decreases in intensity. Note that 5 mg of protein was loaded for cell layers and 50 mg for conditioned media. The
,80-kD V3Nter polypeptide is detected at much higher levels in cell layers than in media. In addition, V2Nter polypeptides are detected as a high
molecular weight smear above the 80 kD marker in conditioned medium. (E) mhAT3FS315 cells transfected with V3Nter cDNA. Cell extracts
incubated at 37uC for 2 hr with N-glycosidase, Sialidase A or buffer alone and probed with the indicated antibodies. Deglycosylation reveals
polypeptides of ,50 and 48 kD detected by anti-FZC18, anti-V5 and anti-DUF-959. A 36 kD polypeptide (arrowheads) is detected by anti-FZC18, anti-
V5, but not by anti-DUF-959. [Anti-FZC18 detects nonspecific polypeptides between 30–40 kD (brackets), consistently with Figure 8G].
doi:10.1371/journal.pone.0001878.g004
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clonogenesis in cancer cells. (A) Reporter gene assays using a
b2catenin-TCF responsive reporter (SUPER8XTOPFLASH, white bars) and
a negative control (SUPER8XFOPFLASH, black bars) in HCT116 cells.
Dose-dependent decrease in CRT is detected in response to increasing
amounts of transiently transfected FZC18 cDNA. Controls include
SFRP1, SFRP5, V3Nter and V2Nter (250 ng cDNA). (B) Immunoblot of
HCT116 cells transiently transfected with increasing amounts of FZC18
cDNA. The blots were probed with the indicated antibodies (right).
Hsc70 is a loading standard. (C) Reporter gene assays using cyclin D1
promoter driving luciferase expression in transiently transfected
HCT116 and HepG2 cells. Results are expressed relative to cells
transfected with empty vector. (D) Colony formation assay in HCT116
cells transfected with FZC18 or V2Nter. Histograms show colony
formation efficiencies.
doi:10.1371/journal.pone.0001878.g005
Figure 6. Ectopic FZC18 binds Wnt3a and suppresses Wnt3a-
dependent activation of b2catenin signaling in vitro. (A and B)
Wnt3a pulls down V3Nter specifically via the FZC18 domain. EBNA-293
cells were cotransfected with V3Nter (A) or V2Nter (B) and His-tagged
mouse Wnt3a. Cell lysates were immunoprecipitated (IP), resolved by
10% PAGE-SDS and immunoblotted with the indicated antibodies. IgGH
and IgGL are immunoglobulin heavy and light chains. (C) Reporter gene
assaysusinga b2catenin-TCFresponsive reporter(SUPER8XTOPFLASH) or
a negative control (SUPER8XFOPFLASH). HEK293T or Huh-7 cells were
cotransfected with Wnt3aandtheindicatedvectors. Results aremeansof
three replicates from a representative experiment. Three independent
experiments were performed. Error bars represent standard deviations.
doi:10.1371/journal.pone.0001878.g006
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showed two polypeptides above the 50 kD marker in 7/7 tumors
(Figure 8C). The tumor sample 01 (TL 01) was included both in
Figure 8B and 8C, showing predominantly proteolyzed forms.
These data show a higher ratio of proteolyzed over full-length
forms in cancerous tissues and a higher ratio of full-length over
proteolyzed forms in normal tissues. Thus, an important fraction
of FZC18 detected by immunohistochemistry in HCCs corre-
sponds to processed C18 polypeptides containing the frizzled CRD
module, implying that the negative correlation between FZC18
Figure 7. FZC18 is negatively associated with Wnt/b2catenin pathway activity in vivo. Immunoperoxidase detection (brown) of FZC18,
glutamine synthetase (GS) or b2catenin in normal and tumor livers. Hematoxylin counter-staining (blue). (A-C) In normal liver, FZC18 (A) is detected
around portal tracts (PT). No FZC18 is seen around central veins (CV). GS (B) is detected around CV. (C) Faint cell-membrane b2catenin. (D–F)
Contiguous sections of tumor liver tissue (TL #325) arising in a cirrhotic nodule. FZC18 (D) is detected in remaining non tumor hepatocytes (NT),
compressed by the expansive growth of the tumor, but not in the tumor (T). GS (E) is strong in T and faint in NT. b2catenin (F) is detected in cell
membranes in NT (thick arrow) and in cytoplasm and nuclei in T (thin arrows) (inset). (G–L) Contiguous sections of tumor liver tissue (TL #04). Nodule-
in-nodule showing faint FZC18 (G), but strong GS (H) staining (asterisks), surrounded by tumor tissue showing strong FZC18, but faint GS staining. (J
and K) Higher magnification. (I) Strong FZC18 staining (inset), associated with membranous b2catenin. (L) Mild FZC18 staining (inset), associated with
cytoplasmic and nuclear b2catenin (arrows).
doi:10.1371/journal.pone.0001878.g007
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substantially corresponds to processed V3C18.
Protein homogenates from the HCC case TL 06 containing
both full-length and proteolyzed forms (Figure 8B) were
fractionated by heparin-affinity chromatography, because C18
binds heparin through C-terminal endostatin [23]. Heparin-
binding full-length (,170 kD) and partially processed FZC18-
containing polypeptides (,130 and ,120 kD) (Figure 8D) were
separated from non heparin-binding ones (Figure 8E). Among non
heparin-binding proteins, a 50 kD polypeptide contained the
FZC18, Tsp-1C18 and DUF-959 epitopes (Figure 8E). Digestion
of endogenous V3C18 with collagenase (Figure 8F) released 80 kD
and 50 kD polypeptides, the reaction being inhibited by EDTA
(Figure 8G), indicating that these polypeptides can be released by a
metalloprotease. Interestingly, a ,26 kD polypeptide was detected
by anti-DUF-959 only (Figure 8G). Its molecular weight is
consistent with DUF-959 (Mr=20 kD). In addition, the anti-
Tsp-1C18 antibody detected three collagenase-resistant polypep-
tides (48; 44 and 32 kD), but not the 50 kD polypeptide
(Figure 8G). Thus, the 50 kD polypeptide released in vitro by
collagenase digestion of endogenous C18 is a partially processed
form of V3C18 containing the FZC18 and DUF-959 modules,
which confirms the existence of V3Nter in vivo.
We previously showed that full-length V2C18 is an abundant
plasma protein secreted by the liver in healthy human subjects [9].
Consistently, unprocessed V3C18 was detected in normal liver
(Figure 8B), suggesting that the periportal signal seen by
immunohistochemistry (Figures 7A and S4A) corresponds mainly
to V3FL. Since V3FL is predominantly detected in liver zones
characterized by low Wnt/b2catenin activity levels (Figure 7, A–
C), it would be tempting to speculate that the expression of V3C18
could be negatively regulated by Wnt/b2catenin signaling.
However, we also showed that some of the FZC18 epitopes may
be masked by sialic acid (Figure 4E). Therefore, antibody-based
analysis of V3C18 does not necessarily reflect expression, as
detection can be influenced by post-translational processing.
Differential topology of FZC18 and DUF-959 in vivo
Consistently with pericellular matrix localization of FZC18 in
vitro, FZC18 highlighted intercellular spaces in human primary liver
cancer tissues (Figure S4B) and was detected either at the surface of
tumorcellsorassupranuclearintracellular material(FigureS4D), as
shown by a tridimensional reconstruction of FZC18 at the cell
surface in human liver cancer case TL 03 (Movie S2). In this case,
cell surface signal likely corresponds to fully proteolyzed FZC18-
containing V3C18 polypeptides, as was shown in Figure 8B.
V3C18 (Figure S4D) and V2C18 (Figure S4E) showed a highly
contrasting topology in contiguous tissue sections from liver
cancer, V3C18 highlighting individual cells and V2C18 outlining
tumor sinusoids. Anti-DUF-959 antibody detects both V3Nter and
V3FL, as well as both V2Nter and V2FL (see eg., Figures 4A and
8A), whereas anti-FZC18 detects FZC18, V3Nter and V3FL.
Bearing this in mind, the highly different signal obtained with
Figure 8. In vivo processing of the N-terminus of V3C18
releases a 50 kD FZC18 precursor. (A) Schematic of V2 and V3 of
C18 showing DUF-959, FZC18, Tsp-1C18 (thrombospondin-1) and ES
(endostatin) modules. Thick horizontal color lines indicate the
antibodies used. (B and C) Histologically representative 5-mm freeze-
dried cryosections from human normal (NL) and tumor livers (TL) were
scraped off slides with sterile scalpels, solubilized in 10% SDS buffer and
dosed. Two hundred mg of whole protein extract was resolved by
denaturing 5% (B) or 12% (C) PAGE-SDS, followed by immunoblot. NLs
show a distinct ,170 kD polypeptide (B). TLs show variable levels of the
,170 kD polypeptide, a prominent polypeptide band below the 74 kD
marker (B) and ,50 to 60 kD bands (C). After membrane stripping,
mouse monoclonal anti-a-tubulin antibody is used as a loading control.
(D–G) A frozen human HCC tissue block (case TL 06, shown in B) was
homogenized using a tissue grinder in non-denaturing buffer
containing protease inhibitors at +4uC. Proteins were clarified by
ultracentrifugation (130 000 g), fractionated by heparin-affinity chro-
matography and analyzed by denaturing 5% (D and F) or 12% (E and G)
PAGE-SDS and immunoblot. (D) 170-kD V3C18 binds heparin with high
affinity. (E) Non heparin-binding polypeptides from the N-terminus of
C18: a ,50 kD polypeptide is detected by the three antibodies (V3Nter,
arrow). (F and G) Digestion of heparin-binding proteins with bacterial
collagenase releases N-terminal noncollagenous polypeptides contain-
ing FZC18 and DUF-959 epitopes. Collagenase activity is inhibited by
EDTA, suggesting that V3Nter can be released by a metalloprotease.
Three identical sample sets were gel-migrated and blotted in parallel,
then cut into 3 stripes before immunodetections. [Anti-FZC18 detects
nonspecific polypeptides between 30–40 kD (brackets)].
doi:10.1371/journal.pone.0001878.g008
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antibodies in contiguous sections of liver cancer was surprising.
Several lines of evidence explain these data.
First, using the normal human total mRNA master panel shown
in Figure 1B, we compared the mRNA expression levels of V2C18
and V3C18 by QRT-PCR. The expression of V3C18 was several
folds lower than that of V2C18 mRNAs. Mean DCT were
12.261.6 for V2C18 and 16.161.3 for V3C18 (p=4.5
28, Mann-
Whitney’s U Test), consistently with previous data showing that
V3 is expressed at very low levels [3,7,27].
Second, we confirmed these data by probing a panel of 8
normal, 12 cancer and 7 inflammatory liver tissues by Northern
blot with
32P-labeled cDNA probes, revealing film exposure times
several folds longer for V3C18 than for V2C18 to detect signal
(data not shown). Thus, given the much higher expression levels of
V2C18 than of V3C18 in all tissues [3,7,27], immunohistochem-
ical detection of endogenous C18 with anti-DUF-959 antibody
reveals the quantitatively predominating V2C18 signal, whereas
anti-FZC18 antibody detects only V3C18. Consistently, compar-
ison of Figure S4, D and E, shows higher signal intensity with anti-
DUF-959 antibody. In addition, as shown in Figure 4E, antibody-
based analysis of V3C18 strictly reveals unmasked FZC18
epitopes. As unmasking of FZC18 can be achieved by clipping
off the sialylated DUF-959 module (Figures 4 and S2) and
immunostaining in tumors reveals mainly proteolytically processed
FZC18-containing polypeptides (Figure 8), the striking differences
between Figures S4, D and E denote differential topology of
FZC18 and DUF-959 modules, respectively.
Discussion
We identified FZC18 as a novel extracellular inhibitor of Wnt/
b2catenin signaling. FZC18 decreases tumor cell growth through
increased cell death in human cancer cell lines carrying activating
b2catenin mutations. In human liver cancers, C18 is processed to
frizzled CRD-containing polypeptides and FZC18 immune reac-
tivity negatively correlates with active Wnt signaling. Moreover,
FZC18 localizes at the cell surface and pulls down Wnt3a in vitro,
suppressing Wnt-dependent activation of b2catenin signaling.
Furthermore, proteolytic processing regulates the biological
activity of FZC18, as full-length C18 does not suppress b2catenin
regulated gene expression.
FZC18 inhibits Wnt signaling in cancer cells carrying
activating b2catenin mutations
We show that exogenous wild-type b2catenin increases CRT,
CCND1 promoter activity and tumor cell survival in HCT116 and
in HepG2 cells carrying heterozygous b2catenin DS45 and D25-
140, respectively, thus lacking key phosphorylable residues in one of
the alleles. Recent reports showed that HCT116 cells express
canonical Wnts [28] and respond to exogenous Wnt1 by increasing
CRT [15]. Thus, oncogenic b2catenin mutations do not saturate
TCF-dependent transcription in cancer cells. Consistently, in
HCT116 and HepG2 cells, SFRP1, SFRP5 and FZC18 decrease
CRT, CCND1 promoter activity and cell survival and thereby
induce cell death. In agreement with our data, overexpression of
SFRP1, SFRP2 and SFRP5 in HCT116 and SW480 CCR cells
destabilize ectopically expressed b2catenin DS45 [15]. Taken
together, these data indicate that FZC18 destabilizes b2catenin in
cells carrying heterozygous b2catenin activating mutations.
FZC18 reduces tumor cell growth
In CRC and HCC cell lines, FZC18 decreases the protein levels
of total and non-phosphorylated b2catenin and downstream
targets, such as cyclin D1 and c-myc. These findings are associated
with ,60% to 70% reduction of tumor cell growth and ,25%
induction of cell death. These data are consistent with the fact that
SFRP1, SFRP2 and SFRP5 suppress Wnt-dependent transcription
by 60%, decrease c-myc mRNA expression, inhibit in vitro tumor
growth and induce cell death in CRC cells carrying oncogenic
mutations of b2catenin [15]. Similarly, SFRP1 sensitizes breast
cancer cells to proapoptotic stimuli [29] and SFRP3 suppresses
tumor growth and cell invasion in prostate cancer cells [30].
Wnt-induced b2catenin stabilization is an important survival
signal which regulates homeostasis [31] and increases the
threshold for contact inhibition and anchorage-independent cell
growth [32]. As a result, reduction in tumor cell growth can be
achieved by either extracellular quenching of Wnts with
monoclonal antibodies [33,34], b2catenin knockdown [35] or
restoring normal APC [36].
FZC18 turns off c-myc in CRC cells, which may explain the
induction of cell death. Indeed, Wnt signaling disables the
checkpoint of c-myc-induced apoptosis in tumor cells [37], thus
enhancing its prooncogenic effects [38]. Although c-myc is a target
of b2catenin in CRCs [39], its link with b2catenin in HCCs
remains controversial [40,41]. In addition, FZC18 turns off cyclin
D1 in CRC and HCC cancer cell lines. Cyclin D1 is a
downstream effector of b2catenin, promoting S-phase entry and
tumor growth [42] and is frequently upregulated in HCCs [41].
The common theme in these approaches is the inhibition of the
Wnt/b2catenin pathway at different levels, providing a rationale
for therapeutic intervention [36]. Particularly, inhibiting Wnt-FZ
interaction at the cell surface was recently indicated as a viable
strategy for anti-cancer treatment [43].
Ectopic FZC18 binds Wnt3a in vitro
We show that ectopically expressed Wnt3a pulls down FZC18 in
vitro and that FZC18 suppresses Wnt3a-dependent activation of
Wnt signaling in human cancer and embryonic kidney cells.
Additionally, homology modeling shows 100% probability that the
FZC18 CRD structure matches FZ8 and SFRP3 CRDs.
Moreover, a peptide lying at the solvent-exposed surface of
FZC18 CRD competes with the FZC18-Wnt3a interaction. This
peptide partially overlaps residues previously shown to be essential
to Wnt-FZ8 interactions [25]. Taken together, these data suggest
that both partners could be associated at the cell surface and favor
the hypothesis of Wnt quenching by FZC18. Alternatively, the
interaction of FZC18 with the cell surface could occur via
heterodimerization with FZ receptors, as has been shown for
SFRPs [44] or through as yet unidentified receptors.
FZC18 is negatively associated with Wnt/b2catenin
pathway activity in vivo
In liver cancers, FZC18 immunostaining negatively correlates
with Wnt/b2catenin signaling and with the protein expression of
the b2catenin-regulated gene GS, consistently with the suppres-
sion of GS synthesis by DKK1 in mice carrying an APC disruption
[13]. Immunohistochemistry with the anti-FZC18 antibody
cannot distinguish between V3FL and processed V3C18 polypep-
tides containing the frizzled CRD. However, immunoblot analysis
showed that V3C18 is predominantly processed in liver cancers,
yielding the FZC18-containing polypeptide V3Nter, which
inhibits Wnt/b2catenin signaling. In addition, small, well-
differentiated liver cancers express higher levels of V3C18 mRNA
than large, less differentiated ones. Taken together, these results
suggest that FZC18 can downregulate b2catenin activation and
expression of downstream genes, such as GS, a marker of
activating b2catenin mutations in HCCs [26]. Consistently, in
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grow faster than GS (2) ones and the GS (+) phenotype is
associated with larger tumors, b2catenin mutations and decreased
apoptosis [45]. As glutamine is critical for the growth of highly
proliferating cells, supporting protein and nucleotide synthesis and
providing a major source of energy [46], GS could make the cell
independent of glutamine supply, conferring a growth advantage.
Bioactive FZC18 is encrypted within and released from
V3C18
The N-terminus of V3C18 undergoes stepwise proteolytic
processing, involving release of a 50 kD biologically active
precursor consisting of DUF-959, FZC18 and part of Tsp-1C18,
that we called V3Nter. Release of V3Nter from endogenous V3C18
was inhibited by EDTA, suggesting that a metalloprotease (MMP)
may be involved in decrypting FZC18 biological activity. MMPs
are major players of ECM proteolysis at the cell surface in tumor
invasion and metastasis, exposing and activating cryptic epitopes
from, e.g., laminins, enhancing cell migration or from plasminogen,
inhibiting angiogenesis. Thus, MMPs precisely control cell
function and are therefore viewed as signaling molecules [47].
V3Nter is N-glycosylated, consistently with previous bioinfor-
matics predictions [3]. Remarkably, sialylation masks some of the
epitopes detected by the anti-FZC18 antibody because the ,50;
,48 and 36 kD polypeptides are only detected after Sialidase A
digestion. Excision of DUF-959 from this precursor releases a
FZC18-containing 36 kD N-glycosylated polypeptide. Wnts and
SFRPs are N-glycosylated [21]. Glycosylation may be involved in
apical cell-surface sorting and secretion of Wnts bound to
lipoprotein particles, thus facilitating long-range signaling [48].
In addition, both N-glycosylation and sialylation may participate
with disulfide bonding in dimerization [49]. Moreover, DUF-959
contains a conserved coiled-coil motif [7], which may be involved
in oligomerization. Thus, glycans and conserved motifs may
regulate the release of soluble and active FZC18.
In summary, we show that C18 contains a functional frizzled
CRD that we named FZC18. The biological activity of FZC18 is
cryptic because full-length frizzled CRD-containing C18 is unable
to inhibit Wnt signaling. Rather, full-length C18 may activate Wnt
signaling regardless of the FZC18 module, as V2FL potently
induces CRT. Human V1C18 is a HSPG and its HS attachment
sites are not variant-specific [8]. Consistently, we show that
V3C18 is a cell surface HSPG in vivo and in vitro. HS enhance Wnt
signaling by raising local concentrations of Wnts at the cell surface,
possibly promoting Wnt interaction with the FZ-LRP receptor
complex [21]. Taken together, these data show for the first time a
collagen containing a cryptic frizzled CRD, which can be released
and activated by proteolysis. Moreover, the expression of frizzled
CRD-containing C18 increases during fibrogenesis and in small,
well-differentiated cancers with a favorable outcome.
Materials and Methods
Cell culture, tissue samples and mRNA expression
analysis
Human CRC cell lines HCT116, HT29 and Caco-2 were
cultured in McCoy’s 5A plus 10% FCS (Invitrogen). Human HCC
cell lines HepG2, Huh-6, Huh-7 [20], HepaRG [50], BC1, BC2
and B16A2 [51] and the mouse HCC cell lines mhAT3F and
mhAT3FS315 [18], were cultured as described. MCF-7,
HEK293T and 293EBNA cells were cultured in DMEM
(Invitrogen), plus 10% FCS. Human tissue samples and mRNA
were obtained as described [10], complying with the guidelines of
the National Steering Committee of HCC (INSERM, Paris).
Relative mRNA expression was assessed using mRNA arrays
hybridized with
32P-labelled cDNAs normalized to 18S under
linear-range conditions [10] or by QRT-PCR using SYBR Green
PCR Master Mix (Applied Biosystems) and the ABI Prism 7000
(Perkin Elmer). Expression was normalized to 18S and to a
calibrator. Primers were designed with Primer 3 on the www.
Sequences and conditions are available on request.
cDNA clones
Full-length V2 and V3 C18 cDNAs were described [7]. Human
V2Nter and V3Nter cDNAs were PCR-cloned in frame with a V5
tag into pcDNA3.1. Mouse V2Nter and V3Nter were cloned into
pREP7 (Invitrogen). Human FZC18 was PCR-cloned in pCRII
(Invitrogen) using V3Nter as a template, excised with EcoRI and
cloned into pSecTag2 (Invitrogen) in frame with an IgK signal
sequence and a C-terminal myc tag. Mouse Wnt1 (pV101, from R.
Nusse) and Wnt3a (in pBSII KS+, from J. Kitajewski) cDNAs were
transferred to pcDNA 3.1 (Invitrogen) in frame with a C-terminal
poly-His tag. SFRP1 and 5 in pcDNA3.1/HisC were from S.
Baylin [15]. Super8XTOP- and Super8XFOP-FLASH reporters
were from R. Moon [52]. The Cyclin D1 promoter reporter D1D-
944pXP2 was from J. Pouyssegur [22]. The normalization Renilla
luciferase vector pGL4.70[hRluc] was from Promega. Wild-type
b2catenin cDNA was from R. Grosschedl [53]. All cDNAs were




4/well) were transfected on 24-well plates with
Lipofectamine Plus (Invitrogen). cDNA was normalized to 250 ng
with the appropriate empty vectors. Super8XTOP/FOP Flash
reporters (15 ng each) or Cyclin D1 promoter reporter (100 ng)
were cotransfected with pGL4.70[hRluc] expressing Renilla
luciferase. After 48 h, luciferase activity was measured in a
scintillation counter (LS6500, Beckman) using the Dual Luciferase
Reporter Assay System (Promega).
Antibodies and immunological methods
Anti-C18 antibodies detected human DUF-959, Tsp-1C18 [8],
FZC18 [7] and endostatin [54] as described and mouse DUF-959
(Saarela et al., unpublished). Monoclonal mouse antibodies were
directed against: Hsc70, c-myc (9E10) and b2catenin (E-5) (Santa
Cruz); non phosphorylated b2catenin (8E4 Upstate), myc and V5
tags (Invitrogen), penta-His tag (Qiagen) and glutamine synthetase
(BD Biosciences). Polyclonal rabbit anti-cyclin D1 was from
Labvision. Secondary antibodies were sheep anti-mouse or goat
anti-rabbit coupled to peroxidase (Biorad) or sheep anti-mouse
and goat anti-rabbit coupled to FITC or TRITC (Sigma),
respectively. Immunoblots and immunohistochemistry were done
as described [9]. Blot image files were processed with MultiGauge
(FujiFilm Lifescience). Microscopes used: Olympus BX60 or
confocal Leica TCS NT system on a Leica DMB microscope.
Color digital files were prepared with Adobe RGB (1998) on
Adobe Photoshop 7.
For immunoprecipitation, mouse His-tagged Wnt3a and mouse
V3Nter or V2Nter cDNAs were cotransfected in HEK 293-EBNA
cells. Cell lysates were incubated with sheep-anti-mouse-IgG-
coated Dynabeads M-280 (Dynal) conjugated with anti-His. After
washing in RIPA buffer, complexes were eluted in denaturing
sample buffer, resolved by 10% PAGE-SDS and immunoblotted
with anti-His antibody (to detect Wnt3a) or with anti-DUF-959 (to
detect V3Nter or V2Nter). To compete with the Wnt3a-V3Nter
interaction, the synthetic peptide RH3 (AWGRFLHTNCHPFLA)
from V3Nter CRD was added to culture media.
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Proteoglycans were purified as described [8]. Briefly, 900 mg
from a frozen tumor was homogenized in 4M guanidine buffer,
clarified by centrifugation and equilibrated in 8M urea buffer.
Proteoglycans were isolated by batch anion-exchange on Q-
Sepharose (GE Healthcare), followed by HiTrap-Q and eluted
with NaCl (0.5M–1.5M). One mg of proteoglycan was digested in
4 mIU of heparin lyase II or III (Sigma), 120 mU of
Chondroitinase ABC, (Seikagaku, Japan) or 20 U of collagenase
(Worthington, USA). Proteins from mhAT3FS315 cells expressing
V2Nter or V3Nter cDNAs were digested with N-glycosidase and
Sialidase A (Glyko Enzymatic Deglycosylation kit, Prozyme).
Heparin-binding proteins were isolated from 500 mg of frozen
human HCC homogenized in non denaturing buffer with protease
inhibitors (Sigma), clarified by ultracentrifugation and applied to a
5-ml HiTrap heparin column. After extensive washing, bound
proteins were eluted stepwise (0.0522M NaCl) [23].
Colony formation assay and flow cytometry
Assays were performed as described [15]. Cells were transfected
using Lipofectamine Plus (Invitrogen), stripped and plated in
triplicates in 100-mm (colony formation) or 6-well plates (flow
cytometry) 24 h after transfection and selected with 0.6 mg ml
21
G148 or 0.5 mg ml
21 zeocin (Invitrogen).
Statistics
Differences between means were assessed by the Mann-
Whitney’s ‘‘U’’ test. Bivariate relationships were calculated by
the Spearman’s rank-order correlation coefficient R or Goodman-
Kruskal’s Gamma (Statistica 7.1, StatSoft 2007).
Supporting Information
Figure S1 V3FL localizes at the cell surface, but does not inhibit
Wnt/ b-catenin signaling. (A) Schematic of V2FL and V3FL
showing DUF-959, FZC18, Tsp-1C18 (thrombospondin-1) and
ES (endostatin) modules. Thick horizontal lines indicate the
antibodies used. (B–D) Overlays of immunofluorescence and phase
contrast confocal microscopy of mhAT3FS315 hepatoma cells
transiently transfected with V3FL (B) or V2FL (C and D) cDNAs
and probed with anti-Tsp-1C18, followed by anti-mouse FITC-
labeled IgG (green). V3FL highlights the cell membranes (B, arrows).
V2FL is detected within the cell (C); by contrast, cell membranes
and intercellular boundaries show no signal (arrows). V2FL (D) is
detected within a large vacuole (v) indented by the nucleus (N)
resembling a Golgi structure. The cell surface shows a secretion
vesicle (arrow) and fraying-like material (arrowhead) suggesting
secretion of V2. (E) Changes in CRT in response to increasing
amounts of transiently transfected cDNA vectors. Reporter gene
assays using a b-catenin-TCF reporter driven by wild-type
(SUPER8XTOPFLASH, white bars) or a negative control with
mutated TCF binding sites (SUPER8XFOPFLASH, black bars).
Results are means of three replicates from a representative
experiment. Three independent experiments were performed.
Error bars represent standard deviations. (F) Reporter gene assays
using a b-catenin-TCF responsive reporter (SUPER8XTOPFLASH)
in human HCC Huh-7 cells (wild-type b-catenin). Results are
means of three replicates from a representative experiment. Three
independent experiments were performed. Error bars represent
standard deviations. P=(Student’s ‘‘t’’ test) indicates statistical
significance with respect to cells transfected with vector alone
(VECTOR). NS, not significant. (G) Left: Protein extracts from a
human HCC (case TL 06, see Figure 8, B, D–G and Figure S4, D
and E) were chromatographed through Q-Sepharose and eluted
with 0.5M (lane 1) and 1M (lane 2) NaCl. Right: One mg from the
1M NaCl fraction was incubated with the indicated enzymes.
Protein samples were resolved by denaturing 5% PAGE-SDS and
immunoblotted. Heparinase digestion results in mobility shift and
epitope unmasking. (H) V2FL and V3FL cDNAs were transiently
transfected in mhAT3FS315 mouse hepatoma cells. Protein
samples from cell layers and from conditioned media were
resolved by denaturing 5% PAGE-SDS and immunoblotted. Both
V2FL and V3FL show a smear-like migration profile typical of
proteoglycans. V2FL is soluble in conditioned medium. V3FL is
detected at high levels in cell layers but is not detected in
conditioned medium. (I) Reporter gene assays using cyclin D1
promoter reporter upstream luciferase cDNA in HCT116 and
HepG2 cells. Results are means of three replicates from a
representative experiment. Three independent experiments were
performed. Error bars represent standard deviations. P=(Stu-
dent’s ‘‘t’’ test) indicates statistical significance with respect to cells
transfected with vector alone (VECTOR). NS, not significant.
Found at: doi:10.1371/journal.pone.0001878.s001 (4.22 MB TIF)
Figure S2 Sialylation of V3Nter resides within the DUF-959
module. (A) Schematic of V2Nter (left) and FZC18 (right) cDNA
vectors and antibodies. Horizontal color lines below each module
denote the antibodies used. (B) Immunoblot of mhAT3FS315 cell
conditioned medium after transfection with FZC18 cDNA.
Proteins were separated in denaturing 7.5% PAGE-SDS. The
asterisk (*) denotes immunoglobulins from FCS-containing
medium. N-glycosidase digestion induces a ,3kD mobility shift
of the FZC18 module detected by anti-FZC18 and by anti-myc tag
antibodies. (C) N-glycosidase and Sialidase A digestion of V2Nter.
Protein extracts from cell layers were incubated at 37 {degree
sign}C for 2 hr with N-glycosidase and Sialidase A or with buffer
alone. Sialidase A reveals polypeptides of ,30 kD and 32 kD.
Found at: doi:10.1371/journal.pone.0001878.s002 (0.76 MB TIF)
Figure S3 A 15-amino acid peptide derived from the CRD of
FZC18 (RH3 peptide) competes with FZC18 binding to Wnt3a.
(A) EBNA-293 cells were cotransfected with mouse V3Nter and
with His-tagged mouse Wnt3a. Transfected cells were incubated
with 0; 50 or 100 mg6ml
21 of the synthetic peptide RH3 from the
CRD domain of FZC18. Cell lysates were analyzed by
immunoblot (10% PAGE-SDS) or coimmunoprecipitated (IP)
with monoclonal anti-His antibody. (B) 3D structure prediction of
the FZC18 CRD and modeling of the potential surfaces involved
in Wnt-FZC18 interactions. SFRP3 and Frizzled-8 CRD crystal
structures were used as templates. The orientation of the CRD
surface on the right is rotated 180u about the vertical axis with
respect to left-side images. Blue, N-termini; gray, C-termini; green,
surfaces involved in Wnt-CRD interactions inferred from
structure-based alignment of FZC18, SFRP3 and FZ8 CRDs
and from described mutations affecting Wnt-CRD binding [25].
Red, localization of the RH3 peptide. Yellow, red and green
overlay. 3D structure prediction was done using the Phyre www
server and Protein Explorer 2.79.
Found at: doi:10.1371/journal.pone.0001878.s003 (1.74 MB TIF)
Figure S4 Detection of FZC18 in human liver. (A) Immunoper-
oxidase staining (brown) in normal human liver shows FZC18 in
periportal hepatocytes. In the portal tract (PT), including portal
veins (v), bile ducts and basement membrane (arrow) no signal is
detected. Case NL 04, shown in Figure 8B. (B) HCC. Speckle-like
FZC18 (arrows) is seen on the surface of tumor cells highlighting
intercellular spaces (case TL 03, shown in Figure 8B). (C) Liver
cirrhosis shows speckle-like FZC18 in hepatocytes (H). No FZC18
is seen in the surrounding stroma (S). (D and E) Case TL 06,
shown in Figure 8, B and D–G. Contrasting topology of FZC18
FZC18 & Wnt Signaling
PLoS ONE | www.plosone.org 12 April 2008 | Volume 3 | Issue 4 | e1878(D) and DUF-959 (E) in HCC. FZC18 highlights the pericellular
matrix (arrows) and is also detected as supranuclear intracellular
material (arrowheads). In the same tumor, DUF-959 outlines cords
of tumor cells highlighting tumor sinusoids (s).
Found at: doi:10.1371/journal.pone.0001878.s004 (9.05 MB TIF)
Movie S1 3D cell surface reconstruction of V3Nter in vitro.
Confocal fluorescence microscopy of mhAT3FS315 mouse liver
cancer cells transiently transfected with V3Nter cDNA and probed
with anti-DUF-959, followed by anti-rabbit TRITC-labeled IgG
(red). Original magnification61000. Fifteen representative images
acquired at 500-nm intervals on the vertical axis were stacked on
ImageJ 1.37v (NIH, USA).
Found at: doi:10.1371/journal.pone.0001878.s005 (0.13 MB
MOV)
Movie S2 3D cell surface reconstruction of FZC18 in vivo.
Reconstruction of FZC18 staining at the cell surface in a human
hepatocellular carcinoma (case TL 03, shown in Figures 8B and
S4B). Original magnification61000. Images were acquired on the
vertical axis and stacked on ImageJ 1.37v (NIH, USA). In the light
of data on Figure 8B, cell surface signal shows proteolyzed FZC18-
containing V3C18 polypeptides.
Found at: doi:10.1371/journal.pone.0001878.s006 (0.13 MB
MOV)
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